U.S. Biospecimen Market Size, Share, and Trends 2026 to 2035

Payal Rabde, a Healthcare Industry Expert, highlights that the U.S. biospecimen market has reached USD 2.28 billion in 2026 and is on track to reach USD 4.88 billion by 2035, advancing at a CAGR of 8.8%. Key U.S. biospecimen market companies shaping the market include BioIVT, Discovery Life Sciences, Thermo Fisher Scientific, while major growth segments span sample type, application, end-user and region.

Last Updated : 20 Nov 2026  |  Report Code : 8995  |  Category : Healthcare   |  Format : PDF / PPT / Excel

1. Market Overview & Sizing

1.1 U.S. Biospecimen Market: Definition and Scope

1.1.1 Market Definition and Scope of Study

1.1.2 Inclusions and Exclusions

1.1.3 Currency, Units and Base Year

1.2 U.S. Biospecimen Market Taxonomy

1.2.1 By Sample Type

1.2.2 By Application

1.2.3 By End User

1.3 U.S. Biospecimen Market Size and Forecast, 2025-2035

1.3.1 Market Value (USD) and Annual Growth

1.3.2 Historical Market Analysis

1.3.3 Market Growth Analysis and CAGR 2026-2035

1.4 U.S. Biospecimen Market Penetration and Maturity Analysis

1.5 Addressable Market Analysis (TAM, SAM, SOM) for U.S. Biospecimen

1.6 U.S. Biospecimen Market Value Chain Analysis

1.7 U.S. Biospecimen Market Ecosystem Analysis

2. Market Dynamics & Opportunities

2.1 U.S. Biospecimen Market Dynamics Overview

2.2 Growth Drivers

2.2.1 Drug discovery grows

2.2.2 FDA push for human-relevant methods

2.2.3 Diagnostics development

2.2.4 Precision medicine

2.3 Market Drivers - Impact & CAGR Contribution (2026-2035)

2.4 Market Restraints

2.4.1 Ethical and consent requirements

2.4.2 Sample quality variability

2.4.3 Logistics

2.4.4 Cost

2.5 Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

2.6 Market Challenges

2.7 Emerging Opportunities

2.7.1 Human cell models

2.7.2 Rare disease samples

2.7.3 Digital marketplaces

2.7.4 Oncology tissue

2.8 Key Trends in the U.S. Biospecimen Market

2.8.1 New Approach Methodologies using human cells

2.8.2 Liquid biopsy sample demand

2.8.3 Rare disease samples

2.8.4 Digital biobank marketplaces

2.8.5 Consent and privacy rules

2.8.6 Longitudinal samples

2.9 Unmet Needs, White Space and Gap Analysis

2.10 Industry Evolution and Transformation of the U.S. Biospecimen Market

3. Segmentation & Forecast

3.1 U.S. Biospecimen Market, by Sample Type (Share %, 2025-2035)

3.1.1 Blood & Blood Products: Market Share and CAGR

3.1.2 Tissue (FFPE & Frozen): Market Share and CAGR

3.1.3 Cells & Cell Lines: Market Share and CAGR

3.1.4 Nucleic Acids & Others: Market Share and CAGR

3.2 U.S. Biospecimen Market, by Application (Share %, 2025-2035)

3.2.1 Drug Discovery & Development: Market Share and CAGR

3.2.2 Diagnostics Development: Market Share and CAGR

3.2.3 Clinical Research: Market Share and CAGR

3.2.4 Academic Research: Market Share and CAGR

3.3 U.S. Biospecimen Market, by End User (Share %, 2025-2035)

3.3.1 Pharma & Biotech Companies: Market Share and CAGR

3.3.2 Diagnostic Companies: Market Share and CAGR

3.3.3 CROs & Academic Institutes: Market Share and CAGR

3.4 Segment Attractiveness and Growth Comparison

4. Regional & Country Intelligence

4.1 U.S. Biospecimen Market: Northeast

4.1.1 Market Size and Forecast, 2025-2035

4.1.2 Market Share by Sample Type

4.1.3 Demand Drivers, Regulation and Local Competition

4.2 U.S. Biospecimen Market: West

4.2.1 Market Size and Forecast, 2025-2035

4.2.2 Market Share by Sample Type

4.2.3 Demand Drivers, Regulation and Local Competition

4.3 U.S. Biospecimen Market: South

4.3.1 Market Size and Forecast, 2025-2035

4.3.2 Market Share by Sample Type

4.3.3 Demand Drivers, Regulation and Local Competition

4.4 U.S. Biospecimen Market: Midwest

4.4.1 Market Size and Forecast, 2025-2035

4.4.2 Market Share by Sample Type

4.4.3 Demand Drivers, Regulation and Local Competition

4.5 Region Attractiveness and Market Entry Assessment

5. Competitive & Company Intelligence

5.1 U.S. Biospecimen Market Competitive Landscape Overview

5.2 Market Share by Company, 2025

5.3 Company Ranking and Competitive Indexing

5.4 Precedence Research Companies Quadrant

5.5 Competitive Benchmarking

5.5.1 Product Portfolio Benchmarking

5.5.2 Geographic Presence Benchmarking

5.5.3 Technology and Innovation Benchmarking

5.6 Strategic Group Mapping

5.7 Barriers to Entry and New Entrant Analysis

5.8 Mergers, Acquisitions and Strategic Partnerships

5.9 Recent Developments in the U.S. Biospecimen Market

6. Pricing Intelligence

6.1 U.S. Biospecimen Market Pricing Overview

6.1.1 Instrument list price and discount analysis

6.1.2 Consumables and reagent pricing per test or sample

6.1.3 Service contract and subscription pricing

6.1.4 Academic vs. biopharma pricing tiers

6.2 Pricing by Sample Type

6.3 Pricing by Region

6.4 Historical Price Trend and Price Forecast, 2025-2035

6.5 Cost Structure, Margin and Price Sensitivity Analysis

6.6 Competitor Pricing Benchmarking

7. Buyer & Customer Intelligence

7.1 U.S. Biospecimen Market Buyer Landscape

7.1.1 Pharmaceutical and biotechnology companies

7.1.2 Academic and government research institutes

7.1.3 CROs, CDMOs and core facilities

7.1.4 Clinical and diagnostic laboratories

7.2 Buyer Segmentation and Purchasing Patterns

7.3 Buying Criteria and Decision-Making Process

7.4 Customer Pain Points and Unmet Needs

7.5 Customer Retention, Switching and Loyalty Analysis

8. Buying, Selling & Procurement

8.1 Procurement Strategies and Supplier Selection Criteria

8.2 Sales Channel Analysis: Direct vs. Indirect

8.3 Distributor and Dealer Network Analysis

8.4 Key Account and Contract Analysis

8.5 Cross-Selling and Upselling Opportunities

9. Supply Chain & Manufacturing

9.1 U.S. Biospecimen Market Supply Chain Mapping

9.1.1 Key raw materials and component sourcing

9.1.2 OEM and contract manufacturing

9.1.3 Distributor and e-procurement channels

9.1.4 Cold chain and logistics requirements

9.2 Supplier Landscape and Concentration

9.3 Manufacturing Footprint and Capacity Analysis

9.4 Supply Chain Risk and Resilience

10. Trade & Distribution

10.1 Import and Export Analysis

10.2 Major Exporting and Importing Countries

10.3 Tariffs, Duties and Trade Regulations

10.4 Distribution Channel Share and E-commerce Analysis

11. Technology & Innovation

11.1 U.S. Biospecimen Market Technology Landscape

11.1.1 Automation and high-throughput workflows

11.1.2 Digital, cloud and AI-enabled analysis

11.1.3 Next-generation platforms and consumables

11.1.4 Patent and IP landscape

11.2 Innovation Pipeline and R&D Investment Analysis

11.3 Technology Adoption and Readiness Analysis

11.4 Future Technology Roadmap

12. Regulatory & Risk

12.1 U.S. Biospecimen Market Regulatory Landscape

12.1.1 Research-use-only vs. IVD regulatory pathways

12.1.2 GMP and quality standards for bioprocessing

12.1.3 Biosafety and laboratory standards

12.1.4 Data integrity and compliance requirements

12.2 Regulatory Risk and Compliance Cost Analysis

12.3 Political, Economic and Supply Risk Assessment

13. Investment & Financial

13.1 U.S. Biospecimen Market Investment Landscape

13.2 Funding, Venture Capital and Private Equity Activity

13.3 M&A Landscape and Valuation Benchmarking

13.4 Revenue Pool and Profit Pool Analysis

13.5 Investment Opportunity Mapping

14. GTM & Commercial Strategy

14.1 Market Entry and Expansion Strategy

14.2 Go-to-Market Strategy by Customer Segment

14.3 Partnership and Commercialisation Opportunities

14.4 Opportunity Prioritisation Matrix

15. Advanced Forecasting & Scenarios

15.1 Scenario-Based Forecast for the U.S. Biospecimen Market (Base, Optimistic, Pessimistic)

15.2 Sensitivity Analysis of Key Assumptions

15.3 Demand-Supply Gap Forecast

15.4 Market Risk and Uncertainty Assessment

15.5 Long-Term Market Outlook to 2035

16. Industry-Specific Intelligence: Life Science Tools

16.1 Research funding and grant analysis

16.2 Biopharma R&D pipeline linkage

16.3 Installed base and consumables pull-through

16.4 Laboratory adoption and workflow analysis

16.5 Clinical translation and IVD potential

16.6 Outsourcing trends in research and manufacturing

17. Company Profiles & Benchmarking

17.1 BioIVT

17.1.1 Company Overview

17.1.2 U.S. Biospecimen Product Portfolio

17.1.3 Financial Performance and Market Share

17.1.4 Recent Developments and Strategy

17.1.5 SWOT Analysis

17.2 Discovery Life Sciences

17.2.1 Company Overview

17.2.2 U.S. Biospecimen Product Portfolio

17.2.3 Financial Performance and Market Share

17.2.4 Recent Developments and Strategy

17.2.5 SWOT Analysis

17.3 Thermo Fisher Scientific

17.3.1 Company Overview

17.3.2 U.S. Biospecimen Product Portfolio

17.3.3 Financial Performance and Market Share

17.3.4 Recent Developments and Strategy

17.3.5 SWOT Analysis

17.4 Precision for Medicine

17.4.1 Company Overview

17.4.2 U.S. Biospecimen Product Portfolio

17.4.3 Financial Performance and Market Share

17.4.4 Recent Developments and Strategy

17.4.5 SWOT Analysis

17.5 Lonza

17.5.1 Company Overview

17.5.2 U.S. Biospecimen Product Portfolio

17.5.3 Financial Performance and Market Share

17.5.4 Recent Developments and Strategy

17.5.5 SWOT Analysis

17.6 Labcorp

17.6.1 Company Overview

17.6.2 U.S. Biospecimen Product Portfolio

17.6.3 Financial Performance and Market Share

17.6.4 Recent Developments and Strategy

17.6.5 SWOT Analysis

17.7 STEMCELL Technologies

17.7.1 Company Overview

17.7.2 U.S. Biospecimen Product Portfolio

17.7.3 Financial Performance and Market Share

17.7.4 Recent Developments and Strategy

17.7.5 SWOT Analysis

17.8 ATCC

17.8.1 Company Overview

17.8.2 U.S. Biospecimen Product Portfolio

17.8.3 Financial Performance and Market Share

17.8.4 Recent Developments and Strategy

17.8.5 SWOT Analysis

17.9 Cureline (ABS Bio)

17.9.1 Company Overview

17.9.2 U.S. Biospecimen Product Portfolio

17.9.3 Financial Performance and Market Share

17.9.4 Recent Developments and Strategy

17.9.5 SWOT Analysis

17.10 iSpecimen

17.10.1 Company Overview

17.10.2 U.S. Biospecimen Product Portfolio

17.10.3 Financial Performance and Market Share

17.10.4 Recent Developments and Strategy

17.10.5 SWOT Analysis

18. Strategic Recommendations

18.1 Recommendations for Manufacturers and Suppliers in the U.S. Biospecimen Market

18.2 Recommendations for Investors

18.3 Recommendations for Buyers and End Users

18.4 Key Success Factors

19. Analyst View & FAQs

19.1 Analyst View on the U.S. Biospecimen Market

19.2 Research Methodology and Data Validation

19.3 Frequently Asked Questions

19.4 Sources and Abbreviations

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The U.S. biospecimen market was valued at USD 2.10 billion in 2025 and is estimated at USD 2.28 billion in 2026. It is projected to reach USD 4.88 billion by 2035.

Answer : The U.S. biospecimen market is expected to grow at a CAGR of 8.8% from 2026 to 2035, driven by drug discovery, human-relevant testing methods, diagnostics and precision medicine.

Answer : Blood and Blood Products leads the U.S. biospecimen market with a 34% share in 2025, because serum, plasma and whole blood are used in most assays.

Answer : The Northeast dominates the U.S. biospecimen market with a 32% share in 2025, while South is the fastest-growing region.

Answer : Key players in the U.S. biospecimen market include BioIVT, Discovery Life Sciences, Thermo Fisher Scientific, Precision for Medicine, Lonza, Labcorp, STEMCELL Technologies, ATCC, Cureline (ABS Bio), and other players.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client